参考文献/References:
[1]Shah NN,Fry TJ.Mechanisms of resistance to CAR T cell therapy[J].Nat Rev Clin Oncol,2019,16(6):372-385.[2]Wang Z,Han W.Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy[J].Biomark Res,2018,6:4.[3]Lee DW,Santomasso BD,Locke FL,et al.ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells[J].Biol Blood Marrow Transplant,2019,25(4):625-638.[4]Alvi RM,Frigault MJ,Fradley MG,et al.Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)[J].J Am Coll Cardiol,2019,74(25):3099-3108.[5]Hao Z,Li R,Meng L,et al.Macrophage,the potential key mediator in CAR-T related CRS[J].Exp Hematol Oncol,2020,9:15.[6]Guo H,Qian L,Cui J.Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome[J].Cancer Biol Med,2021,19(3):333-342.[7]Sachdeva M,Duchateau P,Depil S,et al.Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators[J].J Biol Chem,2019,294(14):5430-5437.[8]Ingelfinger F,De Feo D,Becher B.GM-CSF: Master regulator of the T cell-phagocyte interface during inflammation[J].Semin Immunol,2021,54:101518.[9]Yang D,He Y,Mu?觡oz-Planillo R,et al.Caspase-11 Requires the Pannexin-1 Channel and the Purinergic P2X7 Pore to Mediate Pyroptosis and Endotoxic Shock[J].Immunity,2015,43(5):923-932.[10]Riestra AM,Valderrama JA,Patras KA,et al.Trichomonas vaginalis Induces NLRP3 Inflammasome Activation and Pyroptotic Cell Death in Human Macrophages[J].J Innate Immun,2019,11(1):86-98.[11]Xia X,Wang X,Cheng Z,et al.The role of pyroptosis in cancer: pro-cancer or pro-"host"?[J].Cell Death Dis,2019,10(9):650.[12]Liu Y,Fang Y,Chen X,et al.Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome[J].Sci Immunol,2020,5(43):eaax7969.[13]Ryder CB,Kondolf HC,O’Keefe ME,et al.Chemical Modulation of Gasdermin-Mediated Pyroptosis and Therapeutic Potential[J].J Mol Biol,2022,434(4):167183.[14]Singh JA,Beg S,Lopez-Olivo MA.Tocilizumab for rheumatoid arthritis: a Cochrane systematic review[J].J Rheumatol,2011,38(1):10-20.[15]Karschnia P,Jordan JT,Forst DA,et al.Clinical presentation,management,and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells[J].Blood,2019,133(20):2212-2221.[16]Neelapu SS,Tummala S,Kebriaei P,et al.Chimeric antigen receptor T-cell therapy - assessment and management of toxicities[J].Nat Rev Clin Oncol,2018,15(1):47-62.[17]Maus MV,Alexander S,Bishop MR,et al.Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events[J].J Immunother Cancer,2020,8(2):e001511.[18]Davila ML,Riviere I,Wang X,et al.Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia[J].Sci Transl Med,2014,6(224):224ra25.[19]Liu S,Deng B,Yin Z,et al.Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia[J].Blood Cancer J,2020,10(2):15.[20]Mestermann K,Giavridis T,Weber J,et al.The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells[J].Sci Transl Med,2019,11(499):eaau5907.[21]Weber EW,Lynn RC,Sotillo E,et al.Pharmacologic control of CAR-T cell function using dasatinib[J].Blood Adv,2019,3(5):711-717.[22]Davey AS,Call ME,Call MJ.The Influence of Chimeric Antigen Receptor Structural Domains on Clinical Outcomes and Associated Toxicities[J].Cancers (Basel),2020,13(1):38.[23]Ying Z,Huang XF,Xiang X,et al.A safe and potent anti-CD19 CAR T cell therapy[J].Nat Med,2019,25(6):947-953.[24]Sterner RM,Cox MJ,Sakemura R,et al.Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells[J].J Vis Exp,2019(149):31380838.[25]Razeghian E,Nasution MKM,Rahman HS,et al.A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies[J].Stem Cell Res Ther,2021,12(1):428.[26]Gust J,Ponce R,Liles WC,et al.Cytokines in CAR T Cell-Associated Neurotoxicity[J].Front Immunol,2020,11:577027.[27]Chang PS,Chen YC,Hua WK.Manufacturing highly potent CD20/CD19-targeted iCasp9 regulatable CAR-T cells using the Quantum pBac-based CAR-T (qCART) system for clinical application[J].bioRxiv,2022.[28]Helsen CW,Hammill JA,Lau VWC,et al.The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity[J].Nat Commun,2018,9(1):3049.[29]Helsen C,Lau V,Hammill J,et al.T Cells Engineered with T Cell Antigen Coupler (TAC) Receptors for Haematological Malignancies[J].Blood,2018,132 (Supplement 1):3267.[30]Ecaterina E.Abstract CT247: A phase I/II trial investigating safety and efficacy of autologous TAC T cells targeting HER2 in relapsed or refractory solid tumors (TACTIC-2) [J].Cancer Res,2022,82 (12_Supplement):CT247.[31]Baeuerle PA,Ding J,Patel E,et al.Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response[J].Nat Commun,2019,10(1):2087.[32]Rana J,Perry DJ,Kumar SRP,et al.CAR- and TRuC-redirected regulatory T cells differ in capacity to control adaptive immunity to FVIII[J].Mol Ther,2021,29(9):2660-2676.[33]Zhang Q,Lu W,Liang CL,et al.Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance[J].Front Immunol,2018,9:2359.[34]Baeuerle PA,Ding J,Patel E,et al.Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response[J].Nat Commun,2019,10(1):2087.[35]David S.Abstract CT105: Preliminary safety and efficacy of gavocabtagene autoleucel (gavo-cel,TC-210),a T cell receptor fusion construct (TRuC),in patients with treatment refractory mesothelin overexpressing solid tumors[J].Cancer Res,2021,81 (13_Supplement):CT105.